TY  - JOUR
AU  - Nawroth, T.
AU  - Johnson, R.
AU  - Krebs, L.
AU  - Khoshakhlagh, P.
AU  - Langguth, P.
AU  - Hellmann, N.
AU  - Goerigk, G.
AU  - Boesecke, P.
AU  - Bravin, A.
AU  - Duc, G Le
AU  - Szekely, N.
AU  - Schweins, R.
TI  - Target Nanoparticles for Therapy - SANS and DLS of Drug Carrier Liposomes and Polymer Nanoparticles
JO  - Journal of physics / Conference Series
VL  - 746
IS  - 1
SN  - 1742-6596
CY  - Bristol
PB  - IOP Publ.
M1  - FZJ-2016-07672
SP  - 012069 -
PY  - 2016
AB  - T arget Nano-Pharmaceutics shall improve therapy and diagnosis of severe diseases, e.g. cancer, by individual targeting of drug-loaded nano-pharmaceuticals towards cancer cells, and drug uptake receptors in other diseases. Specific ligands, proteins or cofactors, which are recognized by the diseased cells or cells of food and drug uptake, are bound to the nanoparticle surface, and thus capable of directing the drug carriers. The strategy has two branches: a) for parenteral cancer medicine a ligand set (2-5 different, surface-linked) are selected according to the biopsy analysis of the patient tissue e.g. from tumor.; b) in the oral drug delivery part the drug transport is enforced by excipients/ detergents in combination with targeting materials for cellular receptors resulting in an induced drug uptake. Both targeting nanomaterials are characterized by a combination of SANS + DLS and SAXS or ASAXS in a feedback process during development by synthesis, nanoparticle assembly and formulation.
LB  - PUB:(DE-HGF)16
UR  - <Go to ISI:>//WOS:000409470900069
DO  - DOI:10.1088/1742-6596/746/1/012069
UR  - https://juser.fz-juelich.de/record/825201
ER  -